Head-To-Head Contrast: PharmaCyte Biotech (OTCMKTS:PMCBD) & Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Profitability

This table compares Jasper Therapeutics and PharmaCyte Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-67.64%	-58.53%
PharmaCyte Biotech	N/A	-49.09%	-43.39%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Jasper Therapeutics and PharmaCyte Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	0	0	10	0	3.00
PharmaCyte Biotech	0	0	0	0	0.00

Jasper Therapeutics currently has a consensus price target of $73.38, suggesting a potential upside of 226.40%. Given Jasper Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Jasper Therapeutics is more favorable than PharmaCyte Biotech.

Risk and Volatility

Jasper Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.

Institutional & Insider Ownership

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Jasper Therapeutics and PharmaCyte Biotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$64.46 million	($4.74)	-4.74
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A

Summary

Jasper Therapeutics beats PharmaCyte Biotech on 6 of the 9 factors compared between the two stocks.

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.